In short
Meglumine Gadoterate, also known as gadoteric acid, is a contrast agent used in magnetic resonance imaging (MRI) scans. This article explores recent clinical trials investigating the use of Meglumine Gadoterate in patients with relapsing multiple sclerosis and severe hyponatremia. These studies aim to evaluate the drug's effectiveness in enhancing brain lesion visibility and its potential role in preventing sodium overcorrection in certain medical conditions.
At a glance
- Drug Name
- Meglumine Gadoterate (Gadoteric Acid)
- Primary Use
- Contrast agent for MRI scans
- Administration
- Intravenous injection
- Dosage
- Up to 0.2 ml/kg body weight
- Clinical Trial Applications
- 1. Relapsing Multiple Sclerosis; 2. Severe Hyponatremia
- Main Objectives
- 1. Evaluate new T1 GdE lesions in MS patients; 2. Assess brain changes in hyponatremia patients
- Key Eligibility Criteria
- 1. RMS with recent disease activity; 2. Severe hyponatremia requiring ICU admission
- Safety Considerations
- Already approved for MRI use; specific trial risks not detailed
What is Meglumine Gadoterate?
Meglumine Gadoterate, also known as Gadoteric acid or Gadoterate meglumine, is a medical contrast agent used in radiology. It belongs to a class of drugs called gadolinium-based contrast agents (GBCAs). These substances are used to enhance the quality of magnetic resonance imaging (MRI) scans, making certain tissues or abnormalities more visible to doctors.
Medical Uses
Meglumine Gadoterate is primarily used in magnetic resonance imaging (MRI) procedures. It helps to improve the visibility of internal body structures during MRI scans, which can be crucial for diagnosing various conditions. Some of the medical uses include:
- Detecting and monitoring brain lesions in patients with multiple sclerosis (MS)
- Enhancing the visibility of tumors or other abnormalities in the brain and spine
- Assisting in the diagnosis of various neurological conditions
- Helping to visualize blood vessels and assess blood flow in different parts of the body
How it Works
Meglumine Gadoterate contains gadolinium, a rare earth metal. When injected into the body, it circulates in the bloodstream and accumulates in certain tissues. The gadolinium atoms affect the magnetic properties of nearby water molecules, which results in a brighter or enhanced signal on MRI images. This enhancement allows radiologists to better distinguish between normal and abnormal tissues, making diagnoses more accurate.
Administration
Meglumine Gadoterate is typically administered through intravenous injection (into a vein) just before or during an MRI scan. The dosage is usually calculated based on the patient's body weight, with a typical dose being around 0.2 milliliters per kilogram of body weight. It's important to note that this medication should only be administered by healthcare professionals in a clinical setting.
Safety and Precautions
While Meglumine Gadoterate is generally considered safe, there are some precautions to be aware of:
- Allergic reactions: Although rare, some people may be allergic to gadolinium-based contrast agents. Inform your doctor of any allergies before the procedure.
- Kidney function: Patients with severely impaired kidney function may be at risk of a rare condition called nephrogenic systemic fibrosis (NSF). Your doctor will assess your kidney function before administering the contrast agent.
- Pregnancy and breastfeeding: If you are pregnant or breastfeeding, inform your doctor as special considerations may apply.
Ongoing Research
Meglumine Gadoterate is currently being used in clinical trials to further understand its applications and effectiveness. For example, it's being used in a study investigating new treatments for relapsing multiple sclerosis (RMS). In this study, Meglumine Gadoterate is used to enhance MRI scans, allowing researchers to count the number of new brain lesions in patients with RMS. This helps to evaluate the effectiveness of a new drug being tested for MS treatment.
Another study is using Meglumine Gadoterate in MRI scans to assess potential brain damage in patients who have experienced severe hyponatremia (low sodium levels in the blood). This demonstrates how this contrast agent can be valuable in various areas of medical research and diagnosis beyond its primary use in MS.